Now showing items 1-4 of 4
Targeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkB
Targeted therapy is a promising approach for treatment of neuroblastoma as evident from the large number of targeting agents employed in clinical practice today. In the absence of known crystal structures, researchers rely ...
Transcriptomic landscape of cisplatin-resistant neuroblastoma cells
The efficiency of cisplatin (CDDP) is significantly hindered by the development of resistance during the treatment course. To gain a detailed understanding of the molecular mechanisms underlying the development of cisplatin ...
hNET as a target for neuroblastoma nanomedicine
(Mendel University in Brno, 2017-12-31)
Chemotherapy often results in various side effects, which can negatively affect health. Neuroblastoma, one of the most common types of childhood cancer, is but one of the examples, where side effects of chemotherapeutic ...
Proteomic signature of neuroblastoma cells UKF-NB-4 reveals key role of lysosomal sequestration and the proteasome complex in acquiring chemoresistance to cisplatin
(American Chemical Society, 2019-03-25)
Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying ...